1 | attention | 9,962 |
2 | unresponsiveness | 65 |
3 | cigars | 44 |
4 | attentions | 28 |
5 | diligence | 19 |
6 | asthenopia | 10 |
7 | hammers | 8 |
8 | 'attention | 6 |
9 | hal-fc | 6 |
10 | devotion | 5 |
11 | durotomy | 5 |
12 | repatriation | 4 |
13 | rmgal36 | 4 |
14 | synovia | 4 |
15 | attention/joint | 3 |
16 | dividends | 3 |
17 | intervention-engagement | 3 |
18 | o₂/no | 3 |
19 | perfusion/thickening | 3 |
20 | self-compassionate | 3 |
21 | alfaro | 2 |
22 | alpha-activity | 2 |
23 | clb5/clb6 | 2 |
24 | clinical-ct | 2 |
25 | confabulations | 2 |
26 | eu-wide | 2 |
27 | hyperchloraemia | 2 |
28 | immunocytoma | 2 |
29 | information-attention | 2 |
30 | interest/pleasure | 2 |
31 | pbml | 2 |
32 | placebo+methotrexate | 2 |
33 | serine-309 | 2 |
34 | sulfaisodimidine | 2 |
35 | tdf- | 2 |
36 | vlvi | 2 |
37 | ~3.5-fold | 2 |
38 | 'efficacy-effectiveness | 1 |
39 | 103:9-17 | 1 |
40 | 55-64yr | 1 |
41 | anchor-judgment | 1 |
42 | anti-lipoprotein | 1 |
43 | antilipoprotein | 1 |
44 | atomextine | 1 |
45 | attention- | 1 |
46 | aware/unaware | 1 |
47 | breburg | 1 |
48 | clear.surgery | 1 |
49 | co-drugs | 1 |
50 | component-protein | 1 |
51 | condition-might | 1 |
52 | cross-allergenicity | 1 |
53 | ctp-based | 1 |
54 | c•a | 1 |
55 | dahlbom | 1 |
56 | dibicor | 1 |
57 | domains/motifs | 1 |
58 | ferrous/ferrous- | 1 |
59 | higher-30 | 1 |
60 | innervation/perfusion | 1 |
61 | knobs | 1 |
62 | mep1 | 1 |
63 | mibg/99mtc-tetrofosmin | 1 |
64 | monoclonality | 1 |
65 | non-symbiotically | 1 |
66 | patient-houses | 1 |
67 | pyruvate/malate | 1 |
68 | reasoning-and | 1 |
69 | release±perindopril | 1 |
70 | retrotransposons-contribute | 1 |
71 | risk-benefit-consideration | 1 |
72 | sex-for | 1 |
73 | time-cbv | 1 |
74 | triacetylfusarinine-c | 1 |
75 | ≥€30 | 1 |
1 | 'attention | 6 |
2 | 'efficacy-effectiveness | 1 |
3 | 103:9-17 | 1 |
4 | 55-64yr | 1 |
5 | alfaro | 2 |
6 | alpha-activity | 2 |
7 | anchor-judgment | 1 |
8 | anti-lipoprotein | 1 |
9 | antilipoprotein | 1 |
10 | asthenopia | 10 |
11 | atomextine | 1 |
12 | attention | 9,962 |
13 | attention- | 1 |
14 | attention/joint | 3 |
15 | attentions | 28 |
16 | aware/unaware | 1 |
17 | breburg | 1 |
18 | cigars | 44 |
19 | clb5/clb6 | 2 |
20 | clear.surgery | 1 |
21 | clinical-ct | 2 |
22 | co-drugs | 1 |
23 | component-protein | 1 |
24 | condition-might | 1 |
25 | confabulations | 2 |
26 | cross-allergenicity | 1 |
27 | ctp-based | 1 |
28 | c•a | 1 |
29 | dahlbom | 1 |
30 | devotion | 5 |
31 | dibicor | 1 |
32 | diligence | 19 |
33 | dividends | 3 |
34 | domains/motifs | 1 |
35 | durotomy | 5 |
36 | eu-wide | 2 |
37 | ferrous/ferrous- | 1 |
38 | hal-fc | 6 |
39 | hammers | 8 |
40 | higher-30 | 1 |
41 | hyperchloraemia | 2 |
42 | immunocytoma | 2 |
43 | information-attention | 2 |
44 | innervation/perfusion | 1 |
45 | interest/pleasure | 2 |
46 | intervention-engagement | 3 |
47 | knobs | 1 |
48 | mep1 | 1 |
49 | mibg/99mtc-tetrofosmin | 1 |
50 | monoclonality | 1 |
51 | non-symbiotically | 1 |
52 | o₂/no | 3 |
53 | patient-houses | 1 |
54 | pbml | 2 |
55 | perfusion/thickening | 3 |
56 | placebo+methotrexate | 2 |
57 | pyruvate/malate | 1 |
58 | reasoning-and | 1 |
59 | release±perindopril | 1 |
60 | repatriation | 4 |
61 | retrotransposons-contribute | 1 |
62 | risk-benefit-consideration | 1 |
63 | rmgal36 | 4 |
64 | self-compassionate | 3 |
65 | serine-309 | 2 |
66 | sex-for | 1 |
67 | sulfaisodimidine | 2 |
68 | synovia | 4 |
69 | tdf- | 2 |
70 | time-cbv | 1 |
71 | triacetylfusarinine-c | 1 |
72 | unresponsiveness | 65 |
73 | vlvi | 2 |
74 | ~3.5-fold | 2 |
75 | ≥€30 | 1 |
1 | tdf- | 2 |
2 | attention- | 1 |
3 | ferrous/ferrous- | 1 |
4 | higher-30 | 1 |
5 | ≥€30 | 1 |
6 | mep1 | 1 |
7 | rmgal36 | 4 |
8 | clb5/clb6 | 2 |
9 | 103:9-17 | 1 |
10 | serine-309 | 2 |
11 | hyperchloraemia | 2 |
12 | asthenopia | 10 |
13 | synovia | 4 |
14 | immunocytoma | 2 |
15 | c•a | 1 |
16 | triacetylfusarinine-c | 1 |
17 | hal-fc | 6 |
18 | ctp-based | 1 |
19 | ~3.5-fold | 2 |
20 | reasoning-and | 1 |
21 | diligence | 19 |
22 | eu-wide | 2 |
23 | sulfaisodimidine | 2 |
24 | atomextine | 1 |
25 | aware/unaware | 1 |
26 | interest/pleasure | 2 |
27 | pyruvate/malate | 1 |
28 | self-compassionate | 3 |
29 | placebo+methotrexate | 2 |
30 | retrotransposons-contribute | 1 |
31 | perfusion/thickening | 3 |
32 | breburg | 1 |
33 | vlvi | 2 |
34 | release±perindopril | 1 |
35 | pbml | 2 |
36 | dahlbom | 1 |
37 | component-protein | 1 |
38 | anti-lipoprotein | 1 |
39 | antilipoprotein | 1 |
40 | mibg/99mtc-tetrofosmin | 1 |
41 | innervation/perfusion | 1 |
42 | repatriation | 4 |
43 | risk-benefit-consideration | 1 |
44 | attention | 9,962 |
45 | 'attention | 6 |
46 | information-attention | 2 |
47 | devotion | 5 |
48 | o₂/no | 3 |
49 | alfaro | 2 |
50 | dibicor | 1 |
51 | sex-for | 1 |
52 | 55-64yr | 1 |
53 | knobs | 1 |
54 | dividends | 3 |
55 | patient-houses | 1 |
56 | domains/motifs | 1 |
57 | co-drugs | 1 |
58 | confabulations | 2 |
59 | attentions | 28 |
60 | cigars | 44 |
61 | hammers | 8 |
62 | unresponsiveness | 65 |
63 | 'efficacy-effectiveness | 1 |
64 | clinical-ct | 2 |
65 | condition-might | 1 |
66 | intervention-engagement | 3 |
67 | anchor-judgment | 1 |
68 | attention/joint | 3 |
69 | time-cbv | 1 |
70 | non-symbiotically | 1 |
71 | durotomy | 5 |
72 | clear.surgery | 1 |
73 | cross-allergenicity | 1 |
74 | monoclonality | 1 |
75 | alpha-activity | 2 |